Victhom Human Bionics Inc.
TSX : VHB

Victhom Human Bionics Inc.

January 29, 2007 16:31 ET

Victhom Human Bionics Announces the Filing of a Preliminary Prospectus

QUEBEC, CANADA--(CCNMatthews - Jan. 29, 2007) - THIS PRESS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Victhom Human Bionics Inc. ("Victhom") (TSX:VHB) is pleased to announce that it has filed a preliminary short-form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario and Quebec pursuant to which Victhom proposes to complete a public offering of units for a minimum amount of $10 million. The offering is being made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited. Each unit will consist of one common share of Victhom and one half of one common share purchase warrant. The price of the units and the final terms of the warrants will be agreed upon between the Agents and Victhom prior to filing of the final prospectus.

Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the Neurostep™ in order to register the product with the European and American Health Authorities and for the completion of its development activities to adapt the Neurostep™ CLS Neuromodulator to target high-potential new indications that could include, among others, sleep apnea, obesity and chronic pain.

THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or future financial performance of Victhom and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. Victhom disclaims any intention, and assumes no obligation, to update these forward-looking statements.

Contact Information